HLA Typing for Transplant Market in terms of revenue was estimated to be worth $0.8 billion in 2023 and is poised to reach $1.1 billion by 2028, growing at a CAGR of 6.3% from 2023 to 2028 according to a new report by MarketsandMarkets™. Factors such as the increasing transplants volume worldwide, rising number of transplant & diagnostic centers, technological advancements, government initiatives to boost HLA typing services, rising public -private investments boost research in HLA genotyping, and increased focus of players to enhance their manufacturing & distribution capabilities across emerging countries are likely to support the growth of HLA typing for transplant market during the forecast period.
Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=96374742
Browse in-depth TOC on "HLA Typing for Transplant Market"
159 - Tables
42 - Figures
212 - Pages
Based on the product and service, the reagents & consumables segment held the largest share of the market in 2022.
Based on the product & service, the HLA typing for the transplants market is segmented into software & services, reagents & consumables, instruments. The reagents & consumables segment held the largest share of the global HLA typing for the transplants market in 2022. Growing need for reliable, faster identification of HLA alleles during transplantation is likely to boost the growth of this segment.
Based on technology, the molecular assays segment held the largest share of the market in 2022.
Based on technology, the HLA typing for the transplants market is segmented into molecular assay technologies and non-molecular assay technologies. The molecular assay technology segment captured the largest market share of HLA typing for transplant market by technology. This is attributed the strong adoption of molecular based technology such as NGS and PCR systems for HLA typing among transplant centers, and hospitals and technological and the ability to provide higher resolution HLA typing over serological methods.
Based on the end user, the independent reference laboratories segment accounted for the largest share of this market in 2022.
Based on the end user, the HLA typing for the transplants market is categorized into independent reference laboratories, hospitals & transplant centers , and research laboratories & academic institutes. independent reference laboratories accounted for the largest share of the HLA typing for the transplants market in 2022 owing to the capacity of reference laboratories to process large and volume of sample, presence of expertise performing complex HLA tests and interpreting results offering offering high quality HLA typing services.
North America accounted for the largest share of the HLA typing for transplants market in 2022.
North America accounted for the largest share of the HLA typing for the transplants market in 2022, followed by Europe. The Asia Pacific is estimated to be the fastest-growing regional market for HLA typing for transplants market during the forecast period.
The dominance of North America in HLA typing for transplant market is attributed to the rapid surge in the organ transplantation procedures, strong foothold of players offering transplant diagnostic products (including HLA typing), and rising research collaborations to identify the novel HLA genes and their role in organ transplantation.
Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=96374742
HLA Typing for Transplant Market Dynamics:
Drivers:
- Increasing number of transplant procedures globally
Restraints:
- costs of molecular tests used for HLA typing procedures
Opportunities:
- Technological shift from non-molecular serological assays to gene-based HLA profiling
Challenge:
- Significant gap between organ availability and demand
Key Market Players of Antibody Drug Conjugates Industry:
Some of the prominent players in the HLA typing for the transplants market are Thermo Fisher Scientific (US) Illumina, Inc. (US), QIAGEN (Germany), CareDx (US),F. Hoffmann-La Roche Ltd. (Switzerland),Bio-Rad Laboratories, Inc. (US), Immucor, Inc. (US), Luminex Corporation (US), TBG Diagnostics Limited. (Australia) FUJIREBIO (Japan),Omixon Inc. (US), GenDX (Netherlands), BAG Diagnostics GmbH (Germany), Creative Biolabs (US), and PacBio (US).
Recent Developments:
- In September 2023, Omixon, Inc. (US) launched its NanoTYPE RUO Multiplex Human Leukocyte Antigen Amplification kit compatible with Oxford Nanopore's MinION Platform.
Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=96374742
